BioVersys AGFRA:W33 -0.71%7 ROE % is -33.46% as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100. Among 1,248 Biotechnology companies, BioVersys AG ranks worse than 54.33% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioVersys AG's annualized net income for the quarter that ended in Dec. 2025 was €-23.19 Mil. BioVersys AG's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €69.30 Mil. Therefore, BioVersys AG's annualized ROE % for the quarter that ended in Dec. 2025 was -33.46%.
The historical rank and industry rank for BioVersys AG's ROE % or its related term are showing as below:
FRA:W33'
s ROE % Range Over the Past 10 Years
Min: -175.24 Med: -118.59 Max: -46.66
Current: -46.66
During the past 2 years, BioVersys AG's highest ROE % was -46.66%. The lowest was -175.24%. And the median was -118.59%.
FRA:W33's ROE % is ranked worse than 54.33% of 1248
companies
in the Biotechnology industry
Industry Median: -38.26
vs FRA:W33: -46.66
BioVersys AG (FRA:W33) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
BioVersys AG ROE % Related Terms
BioVersys AG ROE % Historical Data
* Premium members only.
The historical data trend for BioVersys AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG ROE % Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
ROE %
-175.23
-61.94
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
ROE %
0.00
-156.30
-54.63
-33.46
FRA:W33 vs VRTX, REGN, ALNY: ROE % Comparison
For the Biotechnology subindustry, BioVersys AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's ROE % distribution charts can be found below:
* The bar in red indicates where BioVersys AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
BioVersys AG (FRA:W33) has a ROE % of -33.46% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #678 out of 1248 companies in the Biotechnology industry, placing it in the top 54.3%.
Is BioVersys AG's ROE % too high?
BioVersys AG's current ROE % is -33.46%. Based on the distribution chart, BioVersys AG ranks #678 out of 1248 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #678 out of 1248 companies for ROE %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioVersys AG and its competitors. BioVersys AG's current ROE % is -33.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current ROE % of -33.46%. The current ROE % is -33.46%. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current ROE % is -33.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score
Get the complete analysis for FRA:W33
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:W33 has been successfully added to your 